Malin investors cautious on investment doubling in value

Cantillon: Malin prevented from selling stock for at least 180 days under lock-up agreement

Analysts are talking of a price target for Malin of as much as €8.80 – some way off its €10 IPO price but well above Monday’s close at €6. Photograph: Kena Betancurs

Analysts are talking of a price target for Malin of as much as €8.80 – some way off its €10 IPO price but well above Monday’s close at €6. Photograph: Kena Betancurs

 

Dublin-listed life sciences investment company Malin’s market value has risen by 11 per cent – or €28 million – over the past two sessions to almost €276 million.

But it reflects just half of the benefit from the €56 million paper profit the company is sitting on in relation to its investment in UK biotech company Immunocore, which more than doubled in value since it floated on the Nasdaq on Friday.

Immunocore, whose most developed pipeline product is an eye cancer therapy, is one of four priority investments Malin has focused on since the company underwent a massive restructuring in late 2018, following a disappointing performance after its own initial public offering (IPO) in 2015. Malin retains 6 per cent of Immunocore after last week’s IPO, worth $127.4 million (€105.7 million) as of Monday.

Eczema treatment

It’s only of late that Malin has enjoyed some good news, with the company announcing last month that Kymab, another one of the four main investee companies, is to be sold to French drugs giant Sanofi in a deal worth up to $1.45 billion (€1.2 billion). This will result in a $112 million initial payment for Malin’s stake of about 10 per cent, with up to $33 million to follow if Kymab, whose most advanced pipeline product is a potentially lucrative treatment for eczema, meets certain milestones.

Price target

Analysts are talking of a price target for Malin of as much as €8.80 – some way off its €10 IPO price but well above Monday’s close at €6.

But investors have good reason to be cautious on the market debut of Immunocore – especially when Malin and other long-standing investors are prevented from selling stock for at least 180 days under a lock-up agreement.

California-based Poseida Therapeutics, which is working on a treatment for bone marrow cancer and in which Malin retains a 15 per cent stake, floated in New York last July amid much initial excitement. The stock, however, is currently wallowing more than 40 per cent off its IPO price.

The Irish Times Logo
Commenting on The Irish Times has changed. To comment you must now be an Irish Times subscriber.
SUBSCRIBE
GO BACK
Error Image
The account details entered are not currently associated with an Irish Times subscription. Please subscribe to sign in to comment.
Comment Sign In

Forgot password?
The Irish Times Logo
Thank you
You should receive instructions for resetting your password. When you have reset your password, you can Sign In.
The Irish Times Logo
Please choose a screen name. This name will appear beside any comments you post. Your screen name should follow the standards set out in our community standards.
Screen Name Selection

Hello

Please choose a screen name. This name will appear beside any comments you post. Your screen name should follow the standards set out in our community standards.

The Irish Times Logo
Commenting on The Irish Times has changed. To comment you must now be an Irish Times subscriber.
SUBSCRIBE
Forgot Password
Please enter your email address so we can send you a link to reset your password.

Sign In

Your Comments
We reserve the right to remove any content at any time from this Community, including without limitation if it violates the Community Standards. We ask that you report content that you in good faith believe violates the above rules by clicking the Flag link next to the offending comment or by filling out this form. New comments are only accepted for 3 days from the date of publication.